本文报告用人胎肝细胞（ＦＬＣ）治疗５６例次支气管哮喘患者，对照组以常规平喘药物治疗，总有效率为６７．８％，显效以上为２２．６％。治疗组总有效率为９５％，显效以上达８５％，与对照组比较Ｐ＜０．００５，无副作用。结论：ＦＬＣ治疗哮喘可明显提高患者细胞免疫功能，具有抗感染，加强抗生素的作用，不仅可防止或减少哮喘的发作，而且疗效高，作用持久可靠，制作简便，应用安全。 This report reports the treatment of 56 cases of bronchial asthma with human fetal liver cells (FLC), the control group with conventional antiasthmatic drugs, the total effective rate was 67.8%, effective was 22.6%. The total effective rate of the treatment group was 95%, markedly higher than 85%, compared with the control group P <0.005, no side effects. Conclusion: FLC treatment of asthma can significantly improve cellular immune function, with anti-infection, strengthen the role of antibiotics, not only to prevent or reduce the onset of asthma, and high efficacy, long lasting and reliable, simple to create, the application of safety.